RWD’s inhalation anesthesia delivers key advantages over traditional injectable methods: rapid induction and recovery, precise control of depth, low metabolic toxicity, and reduced animal stress for improved welfare. These benefits have led to its global adoption by the scientific community.
The fully integrated TAIJII Series builds on this foundation. Designed for a superior user experience, it features a compact footprint, sleek design, and out-of-the-box operation to provide dependable support for any research setting.
Overview
Why isoflurane inhalation anesthesia is the gold standard for research?
Fast induction, faster recovery: With a blood/gas partition coefficient as low as 1.4, animals reach surgical anesthesia within 1 minute and recover fully in under 1 minute after discontinuation.
Minimal interference, reliable data: Over 98% of the agent is eliminated via respiration, with no clinical impact on liver or kidney function. Ideal for long-term or repeated anesthesia studies, especially in PK/PD and toxicology.
Precise control: Easily change depth or duration in real time to match experimental needs.
Better for critical models: Faster recovery and extubation than IV anesthesia, shortening ICU stays.
Cardio- and neuroprotective benefits: Isoflurane dilates peripheral vessels and reduces ischemia-reperfusion injury, making it ideal for brain and heart studies.
Low stress, easy operation: No pre-restraint needed. Avoid long recovery periods and reduce animal stress significantly. Simplify post-op care and monitoring.
Lab-safe: Non-flammable, non-explosive.